Episode two of the Gastritis and Gastric Cancers chapter works through the four gastric tumor families where histology and molecular driver are the discriminator: adenocarcinoma by Lauren type, MALT versus large B-cell lymphoma, the three gastric neuroendocrine tumors, and GIST as the model targeted-therapy cancer. Each tumor's biology drives its staging and its drug. Board-relevant triggers, molecular markers, and treatment sequences throughout.
Gastric adenocarcinoma and the Lauren classificationHereditary diffuse gastric cancer and CDH1Adenocarcinoma staging and molecular profilingMALT versus large B-cell gastric lymphomaThree types of gastric neuroendocrine tumorGIST molecular biology and risk stratificationTargeted therapy sequences (FLOT, R-CHOP, TKIs)Intestinal-type adenocarcinoma arises from the H. pylori atrophy cascade; diffuse type comes from E-cadherin/CDH1 loss, signet-ring cells, and worse prognosis. Signet-ring histology in a 30s-40s patient with a first-degree relative triggers germline CDH1 testing and prophylactic total gastrectomy.Linitis plastica gives a rigid non-distensible leather-bottle stomach; superficial forceps biopsies miss it because cells sit deep, so non-diagnostic superficial biopsies mandate deeper sampling. Resectable disease gets perioperative FLOT plus D2 dissection; metastatic disease is profiled for HER2, PD-L1, MMR/MSI, and claudin 18.2.MALT lymphoma is H. pylori-driven and eradication is curative in most early stomach-confined cases, but t(11;18) marks non-responders needing radiation or rituximab. Large B-cell lymphoma gets R-CHOP, never antibiotics alone.Gastric NETs sort by gastrin: type 1 from atrophic gastritis (high gastrin, high pH), type 2 from ZES/MEN1 (high gastrin, low pH), both low-risk; type 3 is gastrin-independent on normal mucosa with normal gastrin and is the dangerous one, resected like adenocarcinoma. A normal gastrin flags the highest-risk NET.GIST arises from interstitial cells of Cajal as a fourth-layer (muscle) hypoechoic mass, CD117/DOG1 positive, with no nodal spread so no lymphadenectomy. Rule of fives (size and mitotic count) plus small-bowel site and rupture stratify risk; resect gastric GISTs over 2 cm.GIST drug follows the mutation: KIT-mutant responds to imatinib (exon 11 best, exon 9 higher dose), PDGFRA D842V needs avapritinib, and resistance sequence is imatinib then sunitinib then regorafenib then ripretinib.This is an AI-generated podcast, and some pronunciations may be imperfect. Thank you for your understanding, and we hope you enjoyed this content.
Study the full chapter on Board Pearls, with practice questions, tables and primary-guideline references: Gastritis, Gastric Cancers, and Submucosal Tumors
Read this episode: boardpearls.com/gi/episodes/gastritis-gastric-cancers-smts-ep2
Questions or feedback: [email protected].
- (00:00) - Introduction: histology and driver as discriminator
(00:33) - Adenocarcinoma and the Lauren split(03:44) - Staging and molecular profiling to therapy(05:45) - Gastric lymphoma: MALT versus large B-cell(08:55) - Neuroendocrine tumors sorted by gastrin(11:23) - GIST: molecular biology, ultrasound, and drugs(14:46) - Recap by histology and driver